Clinically Proven Systemic Approach to Pet Joint Health
A Deeper Look at the Newly Published Exclzyme Pet™ Clinical Trial
A new randomized, double-blind, placebo-controlled clinical trial on Exclzyme Pet™ has just been published, and the data tells a richer story than a single headline can capture.
Yes, 92% of dogs showed measurable improvement. But what should interest formulators, ingredient buyers and R&D teams most is how the science holds together:
- Rigorous design
- Biomarker-level evidence of reduced inflammation
- Structural improvement on X-rays
- Clean safety profile from start to finish
The published study delivers exactly the kind of evidence product developers need to build the next generation of clinically credible pet supplements.
A Gold-Standard Design Applied to a Companion Animal Population
The trial included 24 dogs diagnosed with arthritis, split evenly into two groups:
- 12 dogs received 1 g of Exclzyme Pet™ twice daily for 30 days
- 12 dogs received a placebo
Both groups were assessed using a panel of clinically meaningful endpoints rather than a single subjective measure:
- Pain scores
- Degree of lameness
- Weight-bearing capacity
- Joint mobility
- Willingness to hold up the contralateral limb
- Radiological assessment
- C-reactive protein (CRP) as a systemic inflammation biomarker
- Quality of life & mood observations
- Monitoring for adverse events
Few pet supplement studies combine behavioral, functional, structural and biochemical evaluations in a single trial. The breadth of measurement is part of what makes the dataset truly compelling.
Numbers that Reframe the Joint Health Conversation
After 30 days of supplementation, the Exclzyme Pet™ group demonstrated statistically significant improvements across every functional measure.
Lameness, Weight Bearing, Joint Mobility & Pain
- 52% reduction in lameness*
- 46% reduction in weight-bearing issues*
- 49% reduction in joint mobility issues*
- 56% reduction in pain*
- 58% improvement in willingness to hold up the contralateral limb*
Radiological Assessment
Veterinarians use a radiological grading system to assess the severity of joint conditions, such as arthritis, using X-rays or other imaging techniques. It helps evaluate the extent of damage to the bones, cartilage and soft tissues in the joints, providing evidence of true joint change. Radiological assessment also improved significantly over the control group.*
Evidence that Goes Beyond Behavior
The result that deserves more attention than it usually gets? CRP levels. Dogs who received Exclzyme Pet™ had 56% lower serum C-reactive protein (CRP) levels than the control group.*
CRP is a clinically validated systemic inflammation biomarker used across both human and veterinary medicine. A measurable drop in CRP is not a subjective owner observation. It’s blood chemistry, and the CRP outcome anchors Exclzyme Pet™ in territory most pet ingredients can’t claim.
Why the Mechanism Matters
Most legacy joint ingredients in the pet category, including glucosamine and chondroitin, target the availability of cartilage substrates. Exclzyme Pet™ takes a fundamentally different approach. As a systemic enzyme blend, it supports the body’s own inflammation-resolution pathways.*
Exclzyme Pet™ contains:
- Peptizyme SP EN™ and bromelain
Target several of the body’s main inflammation pathways, helping turn down the signals that drive swelling, pain and stiffness* - Papain
Helps break down the proteins that fuel inflammation and supports a balanced immune response* - Amla and rutin
Herbal extracts that support the body’s production of antioxidant molecules*
In short, Exclzyme Pet™ doesn’t just cushion a worn joint. It supports the upstream physiological processes that govern the body’s response to inflammation in the first place.*
For formulators, the mechanism opens the door to broader positioning: joint health, tissue repair, muscle recovery and a healthy inflammatory response, all from one clinically supported ingredient.*
Clean-Label Safety
Across the full 30-day intervention, Exclzyme Pet™ was well tolerated, with no reported adverse events.*
In a category where long-term NSAID use carries real safety trade-offs, a clear tolerability profile combined with genuine effectiveness is a significant advantage.
Quality of Life & Mood: The Outcomes Pet Parents Notice
Beyond pain scores and lab values, the study tracked overall quality of life and mood. The Exclzyme Pet™ group improved on both.*
Translation for product developers: the results consumers experience at home match those measured during the trial. The story you share on the label is the story owners live every day.
Bring Real Science to Your Joint Health Product Line
The pet category’s evidence bar is rising fast. Retail buyers, veterinary recommenders and savvy pet parents are getting sharper about what stands behind every label. The next generation of joint health winners will be ingredient-led, clinically defensible and ready for the questions consumers haven’t even started asking yet.
Exclzyme Pet™ puts your brand ahead of the curve. The newly published study gives your team the kind of evidence the pet category has needed for years: a real clinical trial in dogs that holds up to the same scrutiny as human ingredients. Formulators can build on it. Marketing can talk about it. Regulatory can stand behind it.
Expertise & Quality You Can Count On
Manufactured in NSF GMP, FSSC 22000 and ISO 17025 certified facilities, Exclzyme Pet™ is available in packet and powder formats with the flexibility to fit your delivery system of choice.
Specialty Enzymes & Probiotics has spent 45 years building the kind of ingredient pipeline the category demands:
- Deep fermentation expertise
- Hands-on R&D
- Expert formulation support
- Shortest lead times in the industry
Ready to talk through how Exclzyme Pet™ fits your next product? We are. Reach out now.
